Blog

The Local Pharmacovigilance Contact in Greece: A National Requirement Beyond the EU QPPV

The EU QPPV carries the central accountability for a marketing authorisation holder’s safety system, but Greece also expects a local pharmacovigilance contact. Companies that treat[…]

Social Media and Digital Channels in Pharmacovigilance: What You Own and What You Must Screen

Adverse reactions are now described on company websites, patient forums and social platforms long before they reach a safety department. EU good pharmacovigilance practice makes[…]

Biologics and Batch Traceability: Getting Brand Name and Batch Number Into Every Safety Report

For biological medicines, the safety of a case often depends on which product and which batch the patient received. EU pharmacovigilance guidance therefore asks for[…]

Vaccine Pharmacovigilance: Background Rates, Batch Signals and Administration Errors

Vaccines are given to large, healthy populations, often in campaigns, so coincidental events are reported in volume. EMA’s GVP guidance on vaccines asks marketing authorisation[…]

Benefit-Risk in the PBRER: Writing the Integrated Evaluation That Reviewers Actually Read

The benefit-risk evaluation is the part of a periodic report where a company states its view of the product. ICH E2C(R2) asks for it to[…]

EudraVigilance and EVDAS for Marketing Authorisation Holders: What You Can See and What You Should Do With It

EudraVigilance is the EU system for collecting and analysing suspected adverse reaction reports, and EVDAS is the tool through which marketing authorisation holders (MAHs) can[…]

SUSAR Reporting Under the Clinical Trials Regulation: Clocks, Roles and Common Gaps

Under the EU Clinical Trials Regulation, sponsors report suspected unexpected serious adverse reactions (SUSARs) straight to EudraVigilance, on fixed clocks that start when the sponsor[…]

The DSUR: One Annual Safety Report for an Investigational Medicine, Done Properly

The Development Safety Update Report (DSUR) is the annual safety review that sponsors prepare while a medicine is still in development. Under ICH E2F it[…]

Pregnancy Exposure Reports in Pharmacovigilance: Collecting, Following Up and Classifying

Pregnancy reports are among the most demanding cases in pharmacovigilance. The event may only appear months after the report, the outcome may be normal, and[…]

Safety Data Exchange Agreements: Who Does What, and By When, When Two Companies Share a Product

When a product is licensed, co-marketed, distributed or manufactured under contract, safety information has to travel between companies without delay or loss. The safety data[…]

1 … 9 10 11 12 13 … 34